Last reviewed · How we verify

preservative-free parenteral treprostinil

AOP Orphan Pharmaceuticals AG · Phase 3 active Small molecule

preservative-free parenteral treprostinil is a Prostacyclin analog Small molecule drug developed by AOP Orphan Pharmaceuticals AG. It is currently in Phase 3 development for Pulmonary arterial hypertension (PAH).

Treprostinil mimics the action of prostacyclin, which is a natural substance that dilates blood vessels and prevents platelet aggregation.

Treprostinil mimics the action of prostacyclin, which is a natural substance that dilates blood vessels and prevents platelet aggregation. Used for Pulmonary arterial hypertension (PAH).

At a glance

Generic namepreservative-free parenteral treprostinil
SponsorAOP Orphan Pharmaceuticals AG
Drug classProstacyclin analog
TargetProstacyclin receptor (IP receptor)
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

By binding to and activating prostacyclin receptors, treprostinil promotes vasodilation and reduces pulmonary arterial pressure, thereby improving symptoms and outcomes in patients with pulmonary arterial hypertension.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about preservative-free parenteral treprostinil

What is preservative-free parenteral treprostinil?

preservative-free parenteral treprostinil is a Prostacyclin analog drug developed by AOP Orphan Pharmaceuticals AG, indicated for Pulmonary arterial hypertension (PAH).

How does preservative-free parenteral treprostinil work?

Treprostinil mimics the action of prostacyclin, which is a natural substance that dilates blood vessels and prevents platelet aggregation.

What is preservative-free parenteral treprostinil used for?

preservative-free parenteral treprostinil is indicated for Pulmonary arterial hypertension (PAH).

Who makes preservative-free parenteral treprostinil?

preservative-free parenteral treprostinil is developed by AOP Orphan Pharmaceuticals AG (see full AOP Orphan Pharmaceuticals AG pipeline at /company/aop-orphan-pharmaceuticals-ag).

What drug class is preservative-free parenteral treprostinil in?

preservative-free parenteral treprostinil belongs to the Prostacyclin analog class. See all Prostacyclin analog drugs at /class/prostacyclin-analog.

What development phase is preservative-free parenteral treprostinil in?

preservative-free parenteral treprostinil is in Phase 3.

What are the side effects of preservative-free parenteral treprostinil?

Common side effects of preservative-free parenteral treprostinil include Headache, Nausea, Dizziness.

What does preservative-free parenteral treprostinil target?

preservative-free parenteral treprostinil targets Prostacyclin receptor (IP receptor) and is a Prostacyclin analog.

Related